Point72
VC Fund
Stamford, United States
Point72 is a VC fund in Stamford focused on Biotechnology and Pharmaceutical. Point72 invests in multiple asset classes and strategies worldwide.
- Total investments:
- 46
- Last investment:
- Lead investor:
- 22%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Point72 invests in
Stages Point72 invests in
Countries Point72 invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 19 (41%)
- Pharmaceutical 10 (22%)
- Health Care 8 (17%)
- Therapeutics 7 (15%)
- Software 6 (13%)
Stage
- Post-IPO Equity 12 (26%)
- Series A 6 (13%)
- Series B 6 (13%)
- Series C 6 (13%)
- Series D 3 (7%)
Country
- United States 31 (67%)
- Canada 2 (4%)
- Turkey 2 (4%)
- United Kingdom 2 (4%)
- China 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anup Chamrajnagar
Ventures Investor
|
Ventures Investor | Total investments: 0 | Find email | |
Philip Farese
Senior Researcher
|
Senior Researcher | Total investments: 0 | Find email | |
Steven Cohen
Chairman, Chief Executive Officer, and Co-Chief Investment Officer
|
Chairman, Chief Executive Officer, and Co-Chief Investment Officer | Total investments: 13 | Find email | |
Deirdre Alphenaar
Head of Market Intelligence Integration
|
Head of Market Intelligence Integration | Total investments: 0 | Find email | |
Joel Barron
Head of Product Design
|
Head of Product Design | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| General Intuition is a frontier research lab focused on teaching machines to learn and adapt through play, aiming to build artificial intelligence that can perceive, anticipate, and improvise in real-world dynamics, with gaming as a central domain for testing and innovation. | $220M / Venture - Series Unknown / Sep 29, 2026 | ||
| HubX is a fast-growing tech company focused on building and marketing highly scalable mobile applications. Despite being such a young company, we have a track record of building & growing mobile apps on various verticals that reached over 120 million users across 160 countries.In addition to building apps & in-house tech products, weidentify & invest in promising players in our ecosystem.We're always on the lookout for people that want to be part of our challenging journey to build one of the greatest mobile app studios in the world. If that sounds exciting to you, don't hesitate to apply at https://mobilex.com.tr/caree | $50M / Series A / Aug 28, 2026 | ||
| HubX is a consumer tech company and a developer of mobile applications and a provider of data analytics software. Its operations include the design and construction of mobile and web software products. HubX maintains a central hub that coordinates autonomous studios focused on specific application categories. Its Proprietary technology is utilizedfor revenue tracking and performance optimization across the application portfolio. | $50M / Series A / Aug 28, 2026 | ||
| Databricks is a software platform that helps its customers unify their analytics across the business, data science, and data engineering. It also provides a Unified Analytics Platform for data science teams to collaborate with data engineering and lines of business to build data products. The company was founded in 2013 and is headquartered inSan Francisco, California. | $5B / Private Equity / Aug 13, 2026 | ||
| Uses nuclear fission to create gas and oil from ambient air. | $1B / Series B / Aug 03, 2026 | ||
| SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and moreaffordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small. | $400M / Series G / Apr 09, 2026 | ||
| Rivet Industries delivers front line hardware and software to the world's most important workers. | $57.5M / Series A / Mar 31, 2026 | ||
| Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M / Post-IPO Equity / Mar 17, 2026 | ||
| Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $2B / Series C / Mar 09, 2026 | ||
| Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $140M / Post-IPO Equity / Feb 03, 2026 | ||
| See all 46 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Point72 invest in?
Point72 invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Post-IPO Equity and Series A stage. Most of the 46 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Point72?
Public channels for Point72 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Point72?
The team at Point72 includes Anup Chamrajnagar (Ventures Investor), Philip Farese (Senior Researcher) and Steven Cohen (Chairman, Chief Executive Officer, and Co-Chief Investment Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
